{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:59:03Z","timestamp":1788307143110,"version":"build-2803163510"},"reference-count":111,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.vaccine.2018.01.061","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T13:58:40Z","timestamp":1517925520000},"page":"3541-3554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET)"],"prefix":"10.1016","volume":"36","author":[{"given":"Baldassarre","family":"Martire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Azzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Badolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementina","family":"Canessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Graziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Lorenzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Milito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Panza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Moschese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.01.061_b0005","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2217\/IMT.15.74","article-title":"Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities","volume":"7","author":"Eibl","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.vaccine.2018.01.061_b0010","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s10875-015-0201-1","article-title":"Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency 2015","volume":"35","author":"Picard","year":"2015","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev.immunol.021908.132649","article-title":"Primary B cell immunodeficiencies: comparisons and contrasts","volume":"27","author":"Conley","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0020","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1399-3038.2011.01236.x","article-title":"Modern management of primary B-cell immunodeficiencies","volume":"22","author":"Hoernes","year":"2011","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0025","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1016\/j.vaccine.2014.05.022","article-title":"Vaccine use in primary immunodeficiency disorders","volume":"32","author":"Principi","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.061_b0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.061_b0035","unstructured":"Piano Nazionale Prevenzione Vaccinale. Ministero Della Salute; 2017."},{"key":"10.1016\/j.vaccine.2018.01.061_b0040","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.clim.2007.04.011","article-title":"Active vaccination in patients with common variable immunodeficiency (CVID)","volume":"124","author":"Goldacker","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1128\/CVI.00489-07","article-title":"Serum bactericidal antibody responses to meningococcal polysaccharide vaccination as a basis for clinical classification of common variable immunodeficiency","volume":"15","author":"Rezaei","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0050","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.clim.2005.03.019","article-title":"Immune competence and switched memory B cells in common variable immunodeficiency","volume":"116","author":"Ko","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0055","unstructured":"Centers for Disease Control and Prevention, Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. vol. 60; 2011. p. 1\u201364."},{"issue":"283\u2013284","key":"10.1016\/j.vaccine.2018.01.061_b0060","first-page":"e5","article-title":"Vaccines in the assessment of patients for immune deficiency","volume":"130","author":"Ballow","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0065","doi-asserted-by":"crossref","unstructured":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61: 816\u20139.","DOI":"10.1111\/ajt.12073"},{"key":"10.1016\/j.vaccine.2018.01.061_b0070","doi-asserted-by":"crossref","first-page":"944","DOI":"10.15585\/mmwr.mm6434a4","article-title":"Intervals between PCV13 and PPSV23 vaccines: recommendations of the advisory committee on immunization practices (ACIP)","volume":"64","author":"Kobayashi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.01.061_b0075","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.01.061_b0080","first-page":"305","article-title":"Centers for Disease Control and Prevention (CDC). updated recommendations for the use of typhoid vaccine\u2013advisory committee on immunization practices, United States, 2015","volume":"64","author":"Jackson","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.01.061_b0085","article-title":"Advisory committee on immunization practices. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"49","author":"Prevots","year":"2000"},{"key":"10.1016\/j.vaccine.2018.01.061_b0090","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-3083.2011.02561.x","article-title":"Pandemic influenza vaccination elicits influenza-specific CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports","volume":"74","author":"Pedersen","year":"2011","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0095","series-title":"Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases","author":"Hamborsky","year":"2015"},{"key":"10.1016\/j.vaccine.2018.01.061_b0100","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"136","author":"Bonilla","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0105","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jaci.2013.11.043","article-title":"Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts","volume":"133","author":"Shearer","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0110","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/INF.0000000000000683","article-title":"european society for paediatric infectious diseases consensus recommendations for rotavirus vaccination in Europe","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.01.061_b0115","series-title":"CDC Yellow Book 2016: Health Information for International Travel","author":"Centers for Disease Control and Prevention","year":"2016"},{"key":"10.1016\/j.vaccine.2018.01.061_b0120","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S0140-6736(04)16150-3","article-title":"Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man","volume":"363","author":"MacLennan","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.01.061_b0125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2015.07.025","article-title":"International consensus document (ICON): common variable immunodeficiency disorders","volume":"4","author":"Bonilla","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2018.01.061_b0130","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1016\/j.vaccine.2012.10.035","article-title":"Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka","volume":"30","author":"de Silva","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.061_b0135","unstructured":"American Academy of Pediatrics. Committee on Infectious Diseases, Kimberlin DW, Brady MT, Jackson MA, Long SS. Red BOOK\u202f: 2015 report of the committee on infectious diseases. American Academy of Pediatrics; 2015."},{"key":"10.1016\/j.vaccine.2018.01.061_b0140","unstructured":"Scharenberg AM, Hannibal MC, Torgerson T, Ochs HD, Rawlings DJ. Common Variable Immune Deficiency Overview. GeneReviews Genet Med Genet Inf Resour (Database Online) Copyright, Univ Washington, Seattle 2012; 1993 [n.d.]."},{"key":"10.1016\/j.vaccine.2018.01.061_b0145","first-page":"3121","article-title":"The grey zone between vaccination and immunoglobulin treatment in patients with secondary immunodeficiency","volume":"3","author":"Eibl","year":"2015","journal-title":"Int. Trends Immunity"},{"key":"10.1016\/j.vaccine.2018.01.061_b0150","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/cei.12421","article-title":"Vaccine-associated varicella and rubella infections in severe combined immunodeficiency with isolated CD4 lymphocytopenia and mutations in IL7R detected by tandem whole exome sequencing and chromosomal microarray","volume":"178","author":"Bayer","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0155","first-page":"721","article-title":"Vaccine-associated paralytic poliomyelitis and BCG-osis in an immigrant child with severe combined immunodeficiency syndrome - Texas, 2013","volume":"63","author":"Trimble","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.01.061_b0160","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1401177","article-title":"Transplantation outcomes for severe combined immunodeficiency, 2000\u20132009","volume":"371","author":"Pai","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.01.061_b0165","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jaci.2014.02.028","article-title":"BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies","volume":"133","author":"Marciano","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0170","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1016\/j.vaccine.2010.07.039","article-title":"Severe combined immunodeficiency (SCID) and rotavirus vaccination: Reports to the Vaccine Adverse Events Reporting System (VAERS)","volume":"28","author":"Bakare","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.061_b0175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jaci.2012.04.029","article-title":"Defining combined immunodeficiency","volume":"130","author":"Roifman","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.vaccine.2018.01.061_b0180","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1128\/CVI.00481-09","article-title":"Functional T-cell deficiency in adolescents who experience serogroup C meningococcal disease despite receiving the meningococcal serogroup C conjugate vaccine","volume":"17","author":"Foster","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0185","doi-asserted-by":"crossref","unstructured":"Moinho R, Brett A, Ferreira G, Lemos S. Pneumococcal vaccine failure: can it be a primary immunodeficiency? BMJ Case Rep 2014; 2014: bcr2014204714. doi: 10.1136\/bcr-2014-204714.","DOI":"10.1136\/bcr-2014-204714"},{"key":"10.1016\/j.vaccine.2018.01.061_b0190","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.smim.2014.09.008","article-title":"Mendelian susceptibility to mycobacterial disease: Genetic, immunological, and clinical features of inborn errors of IFN-\u03b3 immunity","volume":"26","author":"Bustamante","year":"2014","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0195","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaci.2008.10.037","article-title":"The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases","volume":"122","author":"Al-Muhsen","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0200","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1002\/eji.200425221","article-title":"Bacillus Calmette Gu\u00e9rin triggers the IL-12\/IFN-\u03b3 axis by an IRAK-4- and NEMO-dependent, non-cognate interaction between monocytes, NK, and T lymphocytes","volume":"34","author":"Feinberg","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0205","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJM199612263352604","article-title":"Interferon-\u03b3 \u2013receptor deficiency in an infant with fatal bacille calmette-gu\u00e9rin infection","volume":"335","author":"Jouanguy","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.01.061_b0210","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1172\/JCI4950","article-title":"Inherited interleukin 12 deficiency in a child with bacille Calmette-Gu\u00e9rin and Salmonella enteritidis disseminated infection","volume":"102","author":"Altare","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2018.01.061_b0215","doi-asserted-by":"crossref","DOI":"10.2350\/16-02-1778-CR.1","article-title":"Disseminated BCG osteomyelitis related to STAT 1 gene deficiency mimicking a metastatic neuroblastoma","author":"Boudjemaa","year":"2016","journal-title":"Pediatr Dev Pathol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0220","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/jmg.2006.044446","article-title":"IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease","volume":"44","author":"Ku","year":"2007","journal-title":"J Med Genet"},{"key":"10.1016\/j.vaccine.2018.01.061_b0225","first-page":"S93","article-title":"Fatal pneumococcal sepsis\/meningitis in seven-year-old girl with IRAK-4 deficiency despite antibiotic prophylaxis and repeated pneumococcal vaccination","volume":"32","author":"Issekutz","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0230","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.dib.2016.02.040","article-title":"Clinical and immunological data of nine patients with chronic mucocutaneous candidiasis disease","volume":"7","author":"Dotta","year":"2016","journal-title":"Data Br"},{"key":"10.1016\/j.vaccine.2018.01.061_b0235","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/pai.12496","article-title":"Novel STAT1 gain-of-function mutation and suppurative infections","volume":"27","author":"Giardino","year":"2016","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0240","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2015-11-679902","article-title":"Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype: an international survey of 274 patients from 167 kindreds","author":"Toubiana","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2018.01.061_b0245","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clim.2007.09.008","article-title":"Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study","volume":"126","author":"Martire","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0250","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MOH.0b013e3282f2bcce","article-title":"Chediak-Higashi syndrome","volume":"15","author":"Kaplan","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0255","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1016\/j.jaci.2009.07.053","article-title":"Primary immunodeficiencies","volume":"125","author":"Notarangelo","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2014.07.012","article-title":"Defective B-cell proliferation and maintenance of long-term memory in patients with chronic granulomatous disease","volume":"135","author":"Cotugno","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0265","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jinf.2012.03.012","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) complications associated with primary immunodeficiency diseases","volume":"64","author":"Norouzi","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2018.01.061_b0270","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/ped.12072","article-title":"Costal BCG osteomyelitis developing 1 year after BCG vaccination","volume":"55","author":"Oyachi","year":"2013","journal-title":"Pediatr Int"},{"key":"10.1016\/j.vaccine.2018.01.061_b0275","doi-asserted-by":"crossref","unstructured":"Lee PP, Lee P. Disseminated bacillus calmette-gu\u00e9rin and susceptibility to mycobacterial infections\u2014implications on bacillus calmette-gu\u00e9rin vaccinations; 2015.","DOI":"10.47102\/annals-acadmedsg.V44N8p297"},{"key":"10.1016\/j.vaccine.2018.01.061_b0280","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jaci.2007.04.034","article-title":"BCG-osis and tuberculosis in a child with chronic granulomatous disease","volume":"120","author":"Bustamante","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0285","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00005792-200005000-00003","article-title":"Chronic granulomatous disease. Report on a national registry of 368 patients","volume":"79","author":"Winkelstein","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.vaccine.2018.01.061_b0290","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1172\/JCI60862","article-title":"CD4(+) T cell vaccination overcomes defective cross-presentation of fungal antigens in a mouse model of chronic granulomatous disease","volume":"122","author":"De Luca","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2018.01.061_b0295","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1128\/CMR.00048-09","article-title":"Infections of people with complement deficiencies and patients who have undergone splenectomy","volume":"23","author":"Ram","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2018.01.061_b0300","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3325\/cmj.2013.54.569","article-title":"Post-vaccine glomerulonephritis in an infant with hereditary C2 complement deficiency: case study","volume":"54","author":"Kersnik","year":"2013","journal-title":"Croat Med J"},{"key":"10.1016\/j.vaccine.2018.01.061_b0305","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1023\/A:1006642611069","article-title":"Phagocytic killing and antibody response during the first year after tetravalent meningococcal vaccine in complement-deficient and in normal individuals","volume":"20","author":"Schlesinger","year":"2000","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0310","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.1365-2249.1998.00738.x","article-title":"Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine","volume":"114","author":"Fijen","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0315","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.vaccine.2015.02.025","article-title":"Immune responses following meningococcal serogroups A, C, Y and W polysaccharide vaccination in C2-deficient persons: Evidence for increased levels of serum bactericidal antibodies","volume":"33","author":"Brodszki","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.061_b0320","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2018.01.061_b0325","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/erv.11.8","article-title":"Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines","volume":"10","author":"Poolman","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.01.061_b0330","article-title":"Immunological disorders in infants & children, 5th edition","volume":"90","author":"Sthiem","year":"2005","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2018.01.061_b0335","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.iac.2008.01.005","article-title":"The hyper-IgE syndromes","volume":"28","author":"Freeman","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.vaccine.2018.01.061_b0340","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jaci.2009.10.013","article-title":"Primary immunodeficiencies: 2009 update","volume":"124","author":"Notarangelo","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0345","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0091-6749(91)90126-9","article-title":"Antibody responses to protein, polysaccharide, and \u03a6X174 antigens in the hyperimmunoglobulinemia E (hyper-IgE) syndrome","volume":"87","author":"Sheerin","year":"1991","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0350","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/0091-6749(88)90873-1","article-title":"Impaired antibody responses in the hyperimmunoglobulin E syndrome","volume":"81","author":"Leung","year":"1988","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0355","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MOH.0b013e32834114bc","article-title":"Clinical spectrum, pathophysiology and treatment of the Wiskott-Aldrich syndrome","volume":"18","author":"Albert","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0360","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1182\/blood-2002-03-0976","article-title":"Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasia","volume":"100","author":"Giovannetti","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2018.01.061_b0365","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1365-2249.2008.03684.x","article-title":"Immunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene","volume":"153","author":"Staples","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0370","unstructured":"Pickering L. Red book 2012 report of the committee on infectious diseases. American Academy of Pediatrics; 2012."},{"key":"10.1016\/j.vaccine.2018.01.061_b0375","unstructured":"Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP). Sindrome IPEX (Immunodysregulation, Polyendocrinopathy, Enteropathy, X-linked) Raccomandazioni diagnostiche e terapeutiche 2009; 2009. p. 9\u201310."},{"key":"10.1016\/j.vaccine.2018.01.061_b0380","doi-asserted-by":"crossref","first-page":"707691","DOI":"10.1155\/2014\/707691","article-title":"Guidelines on vaccinations in paediatric haematology and oncology patients","volume":"2014","author":"Cesaro","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.vaccine.2018.01.061_b0385","first-page":"33","article-title":"Le vaccinazioni nei bambini oncoematologici durante e dopo la chemioterapia","volume":"30","author":"Cesaro","year":"2011","journal-title":"Med E Bambino"},{"key":"10.1016\/j.vaccine.2018.01.061_b0390","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00043426-199809000-00008","article-title":"Immune recovery in children with malignancy after cessation of chemotherapy","volume":"20","author":"Mustafa","year":"1998","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0395","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/sj.leu.2404326","article-title":"Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review","volume":"20","author":"van Tilburg","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.vaccine.2018.01.061_b0400","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/cncr.20384","article-title":"Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy","volume":"101","author":"Zignol","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2018.01.061_b0405","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/pbc.22135","article-title":"Humoral immunity to diphtheria, tetanus, measles, and hemophilus influenzae type b in children with acute lymphoblastic leukemia and response to re-vaccination","volume":"53","author":"Zengin","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.vaccine.2018.01.061_b0410","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/08880010701703511","article-title":"Comparison of accelerated and rapid schedules for monovalent hepatitis B and combined hepatitis A\/B vaccines in children with cancer","volume":"24","author":"K\u00f6ksal","year":"2007","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0415","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/pbc.21106","article-title":"Assessment of the immune response to trivalent split influenza vaccine in children with solid tumors","volume":"49","author":"Bektas","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.vaccine.2018.01.061_b0420","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.ejca.2005.07.006","article-title":"Influenza immunisation in children with solid tumours","volume":"41","author":"Chisholm","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.vaccine.2018.01.061_b0425","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.vaccine.2018.01.061_b0430","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/mpo.2950130205","article-title":"Pneumococcal vaccination in children with acute lymphocytic leukemia","volume":"13","author":"Feldman","year":"1985","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0435","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/pbc.21174","article-title":"Immune response to conjugated meningococcal C vaccine in pediatric oncology patients","volume":"49","author":"Yu","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.vaccine.2018.01.061_b0440","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.01.061_b0445","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/01.mph.0000163214.37147.5a","article-title":"Antibody titers and immune response to diphtheria-tetanus-pertussis and measles-mumps-rubella vaccination in children treated for acute lymphoblastic leukemia","volume":"27","author":"Ercan","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0450","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijid.2003.09.006","article-title":"A review of the varicella vaccine in immunocompromised individuals","volume":"8","author":"Sartori","year":"2004","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.061_b0455","doi-asserted-by":"crossref","DOI":"10.1542\/peds.109.6.e91","article-title":"Current Chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens","volume":"109","author":"Nilsson","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.01.061_b0460","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/00365540310016600","article-title":"Impact of conventional chemotherapy on levels of antibodies against vaccine-preventable diseases in children treated for cancer","volume":"35","author":"Reinhardt","year":"2003","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.061_b0465","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1086\/511636","article-title":"Revaccination of children after completion of standard chemotherapy for acute leukemia","volume":"44","author":"Patel","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.061_b0470","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1365-2141.2009.07903.x","article-title":"Impaired pneumococcal immunity in children after treatment for acute lymphoblastic leukaemia","volume":"147","author":"Lehrnbecher","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0475","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/08880019209006393","article-title":"Varicella vaccine in children with acute lymphoblastic leukemia and non-hodgkin lymphoma","volume":"9","author":"Yeung","year":"2009","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0480","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1651-2227.2006.tb02318.x","article-title":"Avidity of Tetanus and Hib antibodies after childhood acute lymphoblastic leukaemia \u2013 implications for vaccination strategies","volume":"95","author":"Ek","year":"2007","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.vaccine.2018.01.061_b0485","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006484.pub2","article-title":"Influenza vaccination in children being treated with chemotherapy for cancer","author":"Goossen","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2018.01.061_b0490","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1111\/j.1651-2227.2012.02710.x","article-title":"Immunity after (re)vaccination of paediatric patients following haematopoietic stem cell transplantation","volume":"101","author":"Olkinuora","year":"2012","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.vaccine.2018.01.061_b0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2017.06.006","article-title":"Measuring immune response to commonly used vaccinations in adult recipients of allogeneic hematopoietic cell transplantation","author":"Kennedy","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.vaccine.2018.01.061_b0500","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.vaccine.2011.02.018","article-title":"Vaccination of allogeneic haematopoietic stem cell transplant recipients: Report from the International Consensus Conference on Clinical Practice in chronic GVHD","volume":"29","author":"Hilgendorf","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.061_b0505","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2009.263","article-title":"Vaccination of hematopoietic cell transplant recipients","volume":"44","author":"Ljungman","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.vaccine.2018.01.061_b0510","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1016\/j.jaci.2009.08.040","article-title":"Secondary immunodeficiencies, including HIV infection","volume":"125","author":"Chinen","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0515","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.3324\/haematol.2015.126763","article-title":"Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy","volume":"100","author":"Visentin","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.vaccine.2018.01.061_b0520","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10875-014-9995-5","article-title":"Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin?","volume":"34","author":"Dhalla","year":"2014","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0525","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2018.01.061_b0530","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ejim.2014.09.009","article-title":"Should mild hypogammaglobulinemia be managed as severe hypogammaglobulinemia? A study of 389 patients with secondary hypogammaglobulinemia","volume":"25","author":"Blot","year":"2014","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.vaccine.2018.01.061_b0535","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3389\/fimmu.2014.00626","article-title":"Immunoglobulin replacement therapy in secondary hypogammaglobulinemia","volume":"5","author":"Compagno","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0540","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/1042819031000063408","article-title":"Vaccination against infections in chronic lymphocytic leukemia","volume":"44","author":"Sinisalo","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.vaccine.2018.01.061_b0545","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/S0264-410X(00)00409-6","article-title":"Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia","volume":"19","author":"Hartkamp","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.061_b0550","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2141.2001.02882.x","article-title":"Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia","volume":"114","author":"Sinisalo","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.vaccine.2018.01.061_b0555","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1111\/ajt.13505","article-title":"Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2015\u201316 Influenza Season","volume":"15","author":"Grohskopf","year":"2015","journal-title":"Am J Transplant"}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2018.10.056","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:00:00Z","timestamp":1543449600000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1830121X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1830121X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T23:51:13Z","timestamp":1660434673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1830121X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":111,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0264410X1830121X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.061","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}